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ABSTRACT
Background Biannual vitamin A supplementation is 
a well-established survival tool for preschool children 
6 months and older in vitamin A deficient populations 
but this schedule misses the opportunity to intervene 
on most young infant deaths. Randomised trials of 
neonatal vitamin A supplementation (NVAS) in the first 
few days of life to assess its impact on under 6-month 
mortality in low/middle-income countries have had 
varying results.
Methods Investigators of 11 published randomised 
placebo-controlled NVAS trials (n=163 567 children) 
reanalysed their data according to an agreed plan 
and pooled the primary outcomes of mortality from 
supplementation through 6 and 12 months of age 
using random effects models and meta-regression. One 
investigator withdrew but allowed use of the data.
Findings Overall there was no effect of NVAS on 
infant survival through 6 (risk ratio (RR) 0.97; 95% CI 
0.89 to 1.06) or 12 months of age (RR 1.00; 95% CI 
0.93 to 1.08) but results varied by study population 
characteristics.  NVAS significantly reduced 6-month 
mortality among the trials conducted in Southern 
Asia (RR 0.87; 95% CI 0.77 to 0.98), in contexts with 
moderate or severe vitamin A deficiency (defined as 10% 
or higher proportion of women with serum retinol <0.7 
µmol/L or 5% or more women with night blindness) 
(RR 0.87; 95% CI 0.80 to 0.94), early infant mortality 
was 30 or more per 1000 live births (RR 0.91; 95% CI 
0.85 to 0.98), 75% or more of infant mortality occurred 
in the first 6 months of life (RR 0.92; 95% CI 0.84 
to 1.01), or where >32% mothers had no schooling 
(RR 0.88; 95% CI 0.80 to 0.96). NVAS did not reduce 
mortality in the first 6 months of life in trials conducted 
in Africa, in contexts characterised by a low prevalence 
of vitamin A deficiency, lower rates of infant mortality 
and where maternal education was more prevalent. 
There was a suggestion of increased infant mortality 
in trials conducted in Africa (RR 1.07; 95% CI 1.00 to 
1.15).  Individual-level characteristics such as sex, birth 
weight, gestational age and size, age at dosing, parity, 
time of breast feeding initiation, maternal education and 
maternal vitamin A supplementation did not modify the 
impact of NVAS.
Conclusion NVAS reduced infant mortality in South 
Asia, in contexts where the prevalence of maternal 
vitamin A deficiency is moderate to severe and early 
infant mortality is high; but it had no beneficial effect on 
infant survival in Africa, in contexts where the prevalence 
of maternal vitamin A deficiency is lower, early infant 
mortality is low.
INTRODUCTION
Globally, close to 6 million children under 5 died in 
2015; the majority of these deaths occurred in the 
first year of life.1 Despite considerable progress in 
reducing child mortality over the past decade, new 
interventions are needed to accelerate improve-
ments in child survival.
Maternal and child undernutrition is a major risk 
factor for child mortality, accounting for nearly half 
of all under-5 deaths.2 Neonatal vitamin A supple-
mentation (NVAS) has been considered as a poten-
tial intervention to reduce infant mortality. This 
expectation was based on the benefits of vitamin A 
supplementation from 6 months of age in reducing 
later infant mortality and plausible biological mech-
anisms by which this could occur, in addition to 
the observation of widespread maternal vitamin A 
deficiency (VAD) in some regions of the world. The 
WHO recommends periodic vitamin A supplemen-
tation for children aged 6–59 months. It has been 
shown to reduce mortality by 12%–30%3–6 and 
What is already known on this topic?
 ► Vitamin A supplementation of children 6–59 
months in settings where the deficiency is 
a public health problem has been shown to 
reduce mortality.
 ► Supplementation between 1 and 5 months has 
consistently been found as not beneficial.
 ► Supplementation early in the neonatal period 
has been observed to reduce mortality in South 
Asia but not in Africa, for reasons that remain 
unclear.
What this study adds?
 ► Neonatal vitamin A supplementation (NVAS) 
reduced infant mortality in South Asia, in 
contexts where prevalence of maternal vitamin 
A deficiency was of public health importance.
 ► NVAS reduced mortality where there was 
high infant mortality and high percentages of 
mothers never attending school, conditions 
typical of South Asian study sites.
 ► No survival benefit, and possibly harm, was 
suggested in Africa, in contexts where maternal 
deficiency was milder, infant mortality was 
lower, maternal schooling was longer.
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has been implemented in more than 100 countries worldwide.7 
However, trials assessing the effect of supplementation in infants 
aged 1–5 months suggest there is no benefit of supplementation 
in this age group.8–11 Initial randomised trials of NVAS showed 
mixed results regarding their effects on improving survival. Trials 
in Indonesia, Bangladesh and India found significant reductions 
in mortality during the first year of life,12–14 while a small trial 
from Nepal,10 a trial conducted in Zimbabwe15 16 and three trials 
carried out in Guinea-Bissau17–19 found no evidence of benefit. 
Two meta-analyses published in 2011 identified the same seven 
randomised controlled trials,12–18 but reached different conclu-
sions about the effects of NVAS on infant survival.20 21
The WHO convened a technical consultation in December 
2008 to review the existing evidence regarding NVAS. The tech-
nical consultation concluded that there was insufficient evidence 
to inform public health policy. Three additional randomised 
trials were commissioned following its recommendations. The 
publication of these large trials conducted in Ghana, India and 
Tanzania added substantially to the evidence base. While the 
trial conducted in India found a 10% reduction in mortality 
through to 6 months after supplementation,22 the trials in Ghana 
and Tanzania found no survival benefit.23 24 The results of these 
trials were reviewed in the context of pre-existing trials at a 
technical consultation led by the WHO in April 2014. At the 
consultation, experts agreed that it would be important to pool 
the data and explore potential reasons for differences in trial 
results across sites. The trial investigators convened a working 
group in September 2014 to develop the protocol and complete 
this meta-analysis. The analysis plan is available on request. 
Since the meeting, results from a cluster randomised effective-
ness trial conducted in Pakistan were published.25 The Pakistani 
investigators provided their data that have been included in the 
analyses.
The objective of this paper is to present the findings on the 
efficacy of NVAS in reducing mortality under 6 and 12 months 
and how its effects may be modified by study population context 
characteristics in order to inform the development of public 
health recommendations.
METHODS
Potential studies for inclusion in the meta-analysis were identified 
through a systematic review that started with the examination of 
two published meta-analyses of NVAS.20 21 These reviews were 
updated using the Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library), EMBASE, MEDLINE, 
clinical trial websites, conference proceedings, donor agencies, 
experts and researchers, the same search statement as in Gogia 
and Sachdev’s [21] study for identification of any additional 
randomised controlled trials published between 15 October 
2010 and 22 February 2016. Data from a further randomised 
controlled trial were included in the analysis after its publication 
in June 2016.25
The primary outcomes were mortality from date of supple-
mentation to 6 and 12 months. The secondary outcome is to 
examine how its effects may be modified by study-level and 
individual-level characteristics. The primary and secondary 
outcomes remain unchanged during the course of the study.
Eligibility criteria and risk of bias assessment
Individual or cluster randomised trials assessing the effect of early 
NVAS (25 000–50 000 IU intended to be given within the first 
2–3 days of life) compared with placebo, with infant follow-up 
through at least 6 months of age, were eligible for inclusion in 
the meta-analysis. This excluded the West et al’s study as the 
period of supplementation extended beyond 3 days of life.10
Risk of bias in the included studies was assessed following the 
Cochrane Handbook recommendations.
Data collection process
Investigators for each of the identified trials (except the Soofi 
et al’s trial25) met in France in September 2014 to develop a 
harmonised pooled analysis protocol (not available in public 
domain), define subgroups of interest and generate trial-specific 
estimates for each subgroup. The same protocol and definitions 
were used for the Pakistan trial data. For all trials, effect sizes 
were provided as relative risks, except for Pakistan for which 
effects were expressed as ORs.
Statistical methods
The primary outcomes were mortality from date of supplemen-
tation to 6 months and to 12 months.
To ensure comparability between studies, the effect size and 
corresponding 95% CIs were non-parametrically calculated 
using all randomised infants as the denominator for each indi-
vidually randomised trial. Effect sizes and 95% CIs were calcu-
lated using generalised estimating equation logistic regression 
model with log link and exchangeable correlation for the cluster 
randomised trials. Effect sizes were calculated for each study 
overall and for each of the specified subgroups.
We assessed the magnitude of heterogeneity across studies with 
I2 statistics and corresponding p values. We pooled the overall 
study-specific point estimates using random effects models 
because of substantial heterogeneity (I2>50, p for heteroge-
neity <0.05) between studies. Subsequent subgroup analyses to 
explore potential sources of heterogeneity were conducted using 
fixed effects meta-analysis. We compared subgroups using the X2 
statistical test for heterogeneity.
Subgroup analysis
We performed bivariate meta-regression by study-level char-
acteristics to identify populations where the intervention may 
have differential effects. We defined ‘study level characteristics’ 
as the characteristics of the target populations of the studies. 
These included geographic region (Africa or Asia); prevalence of 
maternal VAD which was assessed by study or extant data for a 
country or region, as there being none (0%–1%) or mild preva-
lence (2%–9%) versus having a moderate (10%–19%) or severely 
high (≥20%) prevalence, adapting cut-offs from previous WHO 
guidance for assessing VAD in children26 27; early infant mortality, 
that is, mortality in the control group in the first 6 months of 
life (<30 per 1000 enrolled infants or ≥30 per 1000 enrolled 
infants); ratio of 6-month mortality to 12-month mortality in the 
control group (<75% or ≥75%); proportion of infants given the 
first Diphtheria Pertussis Tetanus vaccine (DPT) dose by 6 months 
(<93% or  ≥93%); and proportion of women who have never 
been to school (<32% or ≥32%). Maternal vitamin A moderate 
or severe status was defined as 10% or more women with serum 
retinol <0.7 mmol/L or 5% or more women with night blindness, 
according to the WHO Global Database on Vitamin A Deficiency.28 
Thresholds to categorise mortality at 6 months, ratio of 6-month 
to 12-month mortality, proportion of infants given first DPT 
by 6 months and the proportion of women who never attended 
school were established by using the median of the distribution of 
the characteristic in the total study population. Meta-analysis and 
meta-regression were performed in STATA (V.13).
To further investigate potential sources of heterogeneity, we 
also performed subgroup analyses by a number of individual-level 
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characteristics. Subgroups of interest included: infant sex (male 
or female); birth weight (<2500 or ≥2500 g); gestational age 
and weight for gestational age categories (preterm small for 
gestational age, term small for gestational age, preterm average 
for gestational age, or term average for gestational age), age 
at vitamin A supplementation (<24 hours, 24–47 hours or 
≥48 hours), parity (1 child, 2–3 children or ≥4 children), 
maternal education (none, primary school, secondary or more 
school), time of breast feeding initiation (≤1 hour, 2–23 hours 
or ≥24 hours), colostrum given (yes or no), and maternal large-
dose vitamin A supplementation (received or not received) and 
maternal serum retinol (<1.05 μmol/L, indicating low to defi-
cient status or ≥1.05 μmol/L, indicating adequate status).
Patient involvement
This manuscript uses data from published studies to address ques-
tions identified in consultation with public health researchers, 
clinicians and nutritionists. In the contributing studies, definition 
of intervention delivery and data collection opportunities consid-
ered patients’ practices and preferences. The intervention was 
delivered at a single contact with the patient and was provided 
free of cost to families. Prior to study initiation, community 
leaders and families in the study areas were engaged by the teams 
that shared information and obtained participants’ consent. At 
the completion of the individual studies, consultations were held 
to disseminate findings and discuss their implications.
RESULTS
We included 11 studies from eight countries: Bangladesh, Ghana, 
Guinea-Bissau (three studies), India (two studies), Indonesia, 
Pakistan, Tanzania and Zimbabwe that met eligibility criteria. 
These trials included a total of 163 567 infants. Nine were indi-
vidually randomised, and two were cluster randomised. Six indi-
vidually randomised trials had two arms, NVAS (48 000–50 000 
IU) and placebo.12 14 18 22–24 One individually randomised trial 
in Guinea-Bissau among low birthweight infants had a facto-
rial design and compared NVAS (25 000 IU) with placebo 
plus early BCG vaccine or on-time BCG vaccine.17 A parallel, 
individually randomised trial in Guinea-Bissau among normal 
birthweight infants was a three-arm trial which compared NVAS 
(50 000 IU), NVAS (25 000 IU) and placebo.19 The individu-
ally randomised trial in Zimbabwe was a 2×2 factorial design 
comparing NVAS (50 000 IU), maternal vitamin A supplementa-
tion (MVAS; 400 000 IU), NVAS plus maternal supplementation, 
and placebo; results were published separately for mothers who 
were HIV positive and HIV negative.15 16 The trial in Bangla-
desh was a cluster randomised trial nested within an MVAS 
trial, and infants were supplemented from birth up to 30 days 
of age (median age at dosing 7 hours (IQR: 2–18)).13 The trial 
in Pakistan was a cluster randomised trial that compared NVAS 
(50 000 IU) with placebo delivered by local health staff.25 All 
identified published trials that met the intervention definition 
and reported on the primary outcome of this joint analysis were 
included. The risk of bias within included studies was deter-
mined to be low (figure 1). Notably, half of the included trials 
published null findings and selective reporting within studies 
was avoided by pooling the data specifically for purposes of this 
meta-analysis.
STUDY CHARACTERISTICS
Study characteristics are summarised in online supplemen-
tary appendix A. Online supplementary appendix B provides 
information on the studies’ populations and individual-level 
prevalence of the effect modifiers examined. Online supplemen-
tary appendix C provides risk ratios per subgroup by site.
RESULTS OF INDIVIDUAL STUDIES
Four studies found reductions in infant mortality between 
supplementation with NVAS and 6 months12–14 22 and seven 
studies15–19 23–25 found no evidence of reduction. Regarding the 
effect of NVAS on mortality through 12 months, two studies 
found reductions in mortality,12 13 while the remaining eight 
studies found no evidence of reduction. One trial did not 
follow-up infants beyond 6 months of age.14
SYNTHESIS OF RESULTS
Overall pooled analysis
After pooling the 11 trials which reported mortality risk at 
6 months, there was no evidence of a reduced risk of death; the 
pooled risk ratio (RR) based on a random effects model was 
0.97; 95% CI 0.89 to 1.06 (table 1 and figure 2).
After combining data from the 10 trials which reported 
mortality by 12 months, there was also no evidence of a reduced 
risk of death; the pooled RR calculated with a random effects 
model was 1.00; 95% CI 0.93 to 1.08 (figure 3).
Pooled results stratified by study-level characteristics
Using meta-regression, we identified five variables as significantly 
associated with the effect of NVAS on mortality at 6 months: 
geographic region of study, prevalence of maternal VAD, control 
group mortality at 6 months, ratio of 6-month to 12-month 
mortality and proportion of mothers with no schooling. 
Geographic region and prevalence of maternal VAD were associ-
ated with the effect of NVAS on mortality by 12 months (table 1).
Geographic region
Based on the five trials conducted in Asia, NVAS was associated 
with a 13% lower risk of death until 6 months (RR 0.87; 95% CI 
0.77 to 0.98). In Africa, based on six trials, the intervention was 
associated with higher, but not statistically significant, risk of 
death (RR 1.06; 95% CI 0.98 to 1.15). Based on four trials in 
Asia which followed infants through 12 months, NVAS was asso-
ciated with a 9% lower risk of infant death (RR 0.91; 95% CI 
0.80 to 1.03), but this was not statistically significant. In Africa, 
based on six trials, NVAS was associated with 7% higher risk of 
death through 12 months (RR 1.07; 95% CI 1.00 to 1.15).
Maternal VAD
NVAS was associated with 13% lower mortality to 6 months in 
the pooled results from three trials conducted in study popu-
lations where the prevalence of maternal VAD was moderate/
severe (RR 0.87; 95% CI 0.80 to 0.94), but not in the pooled 
results from seven trials conducted in study populations with no 
or mild deficiency (RR 1.05; 95% CI 0.96 to 1.15). We observed 
similarly contrasting results regarding mortality through 12 
months. In study populations where the prevalence of maternal 
VAD was moderate or severe, two trials observed a 9% reduc-
tion in mortality (RR 0.91; 95% CI 0.83 to 1.00); in the seven 
study populations with no or mild maternal deficiency, mortality 
was 6% higher but this was not statistically significant (RR 1.06; 
95% CI 0.98 to 1.15).
Control group mortality at 6 months and ratio of mortality to 
6 and 12 months 
Among six trials conducted in study populations where 6-month 
mortality in the control group was 30 or more per 1000 live 
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births, we found a 9% lower risk of death up to 6 months of 
age with NVAS (RR 0.91, 95 CI% 0.85 to 0.98); but we found 
a non-significant 8% higher risk of death among the five trials 
conducted in populations where 6-month mortality in the 
control group was under 30/1000 (RR 1.08; 95% CI 0.95 to 
1.24). Further, among six trials conducted in populations where 
75% or more of infant mortality occurred in the first 6 months, 
there was evidence of lower mortality associated with NVAS 
(RR 0.92; 95% CI 0.84 to 1.01), but this was not statistically 
significant. The opposite was seen among four trials conducted 
in populations where less than 75% of infant mortality occurred 
in the first 6 months (RR 1.11; 95% CI 1.00 to 1.22).
Maternal education
Among four trials conducted in study populations where the 
≥32% of mothers had never been to school, we found a 12% 
lower risk of death in the first 6 months of life with NVAS (RR 
0.88; 95% CI 0.80 to 0.96); but we found no difference in the 
risk of death among the five trials conducted in populations 
where <32% of mothers had never been to school (RR 1.04; 
95% CI 0.92 to 1.18).
Pooled results stratified by individual-level characteristics
Meta-analyses of effects of NVAS at 6 and 12 months stratified 
by 11 individual-level characteristics (sex, birth weight, size 
for gestation, age at dosing, parity, maternal education, time of 
breast feeding initiation, colostrum given, MVAS and maternal 
night blindness) did not show any significant heterogeneity 
between subgroups. The only exception was stratification by 
maternal serum retinol at baseline, which showed significant 
heterogeneity (p=0.042) in effects of NVAS among infants 
born to mothers with low to deficient (RR 0.73; 95% CI 0.51 
to 1.05) and adequate status (RR 1.26; 95% CI 0.86 to 1.84), 
thus suggesting effect modification. However, the RR was not 
significant in either of the two subgroups (table 2).
While there was no indication that size for gestation and 
maternal night blindness are significant effect modifiers, two 
individual subgroups by these characteristics showed signifi-
cant effects. NVAS significantly reduced the risk of death under 
6 months among term small for gestational age infants (RR 0.86; 
95% CI 0.77 to 0.97) but not among other subgroups by size 
and gestation in pooled results from six studies. NVAS also 
significantly reduced risk of death by 6 months in four studies 
among infants of mothers who reported no night blindness (RR 
0.90; 95% CI 0.82 to 0.98), but not significantly so in mothers 
who reported night blindness (RR 0.89; 95% CI 0.64 to 1.26) 
(table 2).
There was no significant benefit or harm identified for any 
of the subgroups by individual-level characteristics regarding 
mortality through 12 months (table 2). Online supplementary 
appendix C provides information on the estimates of the effects 
of NVAS on 6 and 12-month mortality for each study in the 
subgroups.
DISCUSSION
The pooled effect estimates from all studies indicate that 
NVAS had no overall benefit in reducing mortality through 
6 or 12 months of age. A similar finding was reported by 
Haider et al in their 2017 systematic review.29 However, there 
was significant heterogeneity, suggesting that the effects of NVAS 
on survival are influenced by study population characteristics.
Figure 1 Summary of methodological quality of included studies (‘+’ indicates low risk of bias and ‘−’ indicates high risk of bias).
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Most studies conducted in Asia showed benefits for survival 
(RR 0.87; 95% CI 0.77 to 0.98) in the first 6 months of life, 
but no significant effect at 12 months (RR 0.91; 95% CI 0.80 
to 1.03). In Africa, however, none of the studies showed bene-
fits, and the overall results could not rule out the possibility 
of it causing harm (RR 1.06, 95% CI 0.98 to 1.15 for the first 
6 months; and RR 1.07, 95% CI 1.00 to 1.15 for the first 12 
months).
We propose that geography is a marker of differences in study 
population contexts. In Asia, studies were conducted in popu-
lations with a higher prevalence of maternal VAD, higher early 
infant mortality, higher proportion of infant deaths within the 
first 6 months of life and lower levels of maternal schooling. In 
Africa, on the other hand, study populations lived in contexts 
that had a lower prevalence of maternal VAD, lower infant 
mortality, lower early proportion of infant deaths in the first 
Figure 2 Pooled effect of neonatal vitamin A supplementation (NVAS) on mortality between randomisation and 6 months of age in all studies. 
Figure 3 Pooled effect of neonatal vitamin A supplementation (NVAS) on mortality between randomisation and 12 months of age in all studies.
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6 months and higher levels of maternal schooling. The differ-
ences in observed effects of NVAS between the two continents 
are likely to reflect, to some extent, the underlying differences in 
the contexts where populations were studied.
We found that NVAS reduced mortality in populations classi-
fied as having a moderate/severely high prevalence of maternal 
VAD, defined as 10% or higher proportion of women with serum 
retinol <0.7 mmol/L or 5% or more women with night blind-
ness. Notably, all the studied populations meeting this preva-
lence threshold were in Southern Asia. This finding was partially 
supported by meta-analysis using individual-level characteristics, 
which suggested that baseline maternal retinol level may be an 
effect modifier for the effect of NVAS. However, maternal night 
blindness at individual level did not modify the effect of NVAS, 
as maternal night blindness was treated when detected during 
pregnancy in the trials.
We observed that studies conducted in contexts with higher 
early infant mortality showed a significant benefit of NVAS, an 
observation already made by Haider and Bhutta in their 2011 
systematic review.20 The mechanisms underlying this effect of 
NVAS on mortality are unclear. There are plausible ways through 
which NVAS could reduce severity of infection and mortality. 
Neonates in undernourished populations tend to be vitamin A 
deficient by conventional plasma indicators.30 In South India, 
where newborn vitamin A supplementation lowered mortality 
by 22%,14 case fatality from diarrhoea and fever was reduced by 
40%–50% during the first 6 months,31 possibly reflecting anti-
oxidant and anti-inflammatory roles of vitamin A in preserving 
intestinal tract defenses.32–34 In the same study, newborn vitamin 
A also halved the risk of incident nasopharyngeal pneumococcal 
colonisation from 2 to 4 months of age,35 suggestive of strength-
ened postnatal respiratory defenses. An alternative mechanism, 
suggested in published literature, that may explain the differences 
in Asia and Africa is that NVAS has harmful effects in females 
after they receive DPT vaccine, and the proportion of infants who 
receive DPT vaccine on time was higher in African study sites.36
Meta-analyses by individual-level characteristics that could be 
proxies for infant vitamin A status did not support the hypothesis 
that NVAS efficacy is modified by maternal or newborn baseline 
vitamin A status. Low birthweight infants and preterm infants 
in this analysis, either appropriate or small for gestational age, 
who would have lower vitamin A stores than their normal birth 
weight and term peers,37 38 did not show benefit from NVAS. 
We acknowledge, nonetheless, that the data on gestational age 
had limitations. Similarly, we did not find a significant benefit 
of NVAS among infants whose mothers had not received post-
partum MVAS. However, the validity of postpartum MVAS 
programmes as a proxy for maternal vitamin A status is not clear, 
as it may depend on a mother’s pre-existing level of VAD and 
quality of programme implementation. In fact, a subgroup 
analysis among participants in the Tanzania trial found that the 
effect of NVAS was modified by both postpartum MVAS and the 
amount of vitamin A that women consumed through food.39
We must acknowledge that the associations derived from 
meta-regressions are observational, and do not have the strength 
of causal relationships derived from randomised compari-
sons. This has been noted to apply particularly when averages 
of patient characteristics in each trial are used as covariates in 
the regression. We must also acknowledge that we conducted 
many subgroup analyses, and some of the significant differences 
between subgroups may have occurred by chance.
There are many strengths of this analysis. We included data 
from all published trials of NVAS, bringing together informa-
tion from over 160 000 newborns in eight different countries. I
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The trial-specific subgroup analysis was conducted by the inves-
tigators themselves following a jointly agreed plan on using 
individual data records. Study-specific relative risks for each 
subgroup were calculated using the same definitions and methods 
for every study, ensuring that observed heterogeneity was not 
due to analytical differences in the way the effect estimates were 
calculated. One major limitation is that we lack individual-level 
data on the maternal vitamin A status for most mothers in the 
trials. Such data would have allowed us to better examine the 
hypothesis that the efficacy of NVAS is modified by maternal 
vitamin A status. Although five studies assessed serum retinol in 
a subset of subjects, due to the small sample sizes for each study 
there was insufficient power to conduct a subgroup analysis 
based on these data in two of these five studies. We did consider 
analysing continuous data in meta-regression but did not take 
this approach as data points were very few.
Our pooled analyses reveal the absence of an overall benefit 
of NVAS on mortality, but show substantial heterogeneity in the 
effect. This heterogeneity is best explained by the characteristics 
of study populations’ contexts, suggesting that NVAS is beneficial 
in South Asian contexts where the prevalence of maternal VAD is 
moderate to severe, early infant mortality is high (exceeding 
30 deaths per 1000 live births) and maternal schooling is low. 
On the other hand, no benefit to survival, and even a possibility 
of harm, is observed in African contexts where maternal VAD is 
absent or only a mild public health concern, infant mortality is 
lower, and levels of maternal schooling are higher.
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